This document is scheduled to be published in the Federal Register on 2026-11-17 and available online at https://www.federalregister.gov/d/2026-23367, and on https://govinfo.gov

4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2026-P-2305]

Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that M.V.I. PEDIATRIC (ascorbic acid 80 milligrams (mg)/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride equivalent (EQ) 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial, for injection, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Molly Arndt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6281, Silver Spring, MD 20993-0002, Molly.Arndt@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a

generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the "Approved Drug Products With Therapeutic Equivalence Evaluations," which is known generally as the "Orange Book." Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, is the subject of NDA 018920, held by Hospira Inc., and initially approved on April 6, 1983. M.V.I. PEDIATRIC is indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.

In a letter dated September 29, 2021, Hospira Inc. notified FDA that M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was being discontinued, and FDA moved the drug product to the "Discontinued Drug Product List" section of the Orange Book. In a letter dated January 17, 2025, Hospira Inc. requested withdrawal of NDA 018920 for M.V.I. PEDIATRIC (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; phytonadione; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin A; vitamin E). In the *Federal Register* of August 4, 2025 (90 FR 36440), FDA announced that it was withdrawing approval of NDA 018920, effective September 3, 2025.

Apotex, Inc. submitted a citizen petition dated March 4, 2026 (Docket No. FDA-2026-P-2305), under 21 CFR 10.30, requesting that the Agency determine whether M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was not withdrawn for reasons of safety or effectiveness. The petitioner

has identified no data or other information suggesting that this drug product was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have reviewed the available evidence and determined that this drug product was not withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, in the "Discontinued Drug Product List" section of the Orange Book. The "Discontinued Drug Product List" delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to this drug product may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026-23367 Filed: 11/16/2026 8:45 am; Publication Date: 11/17/2026]